Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What makes a CGRP2 receptor?

D L Hay1

  • 1Proteomics and Biomedicine Research Group, School of Biological Sciences, University of Auckland, Auckland, New Zealand. dl.hay@auckland.ac.nz

Clinical and Experimental Pharmacology & Physiology
|August 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Concise Guide to PHARMACOLOGY 2013/14: overview.

British journal of pharmacology·2014
Same author

PACAP receptor pharmacology and agonist bias: analysis in primary neurons and glia from the trigeminal ganglia and transfected cells.

British journal of pharmacology·2013
Same author

Receptor activity-modifying protein-dependent effects of mutations in the calcitonin receptor-like receptor: implications for adrenomedullin and calcitonin gene-related peptide pharmacology.

British journal of pharmacology·2013
Same author

CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?

British journal of pharmacology·2013
Same author

Identification of key residues involved in adrenomedullin binding to the AM1 receptor.

British journal of pharmacology·2013
Same author

Receptor activity-modifying protein-dependent impairment of calcitonin receptor splice variant Δ(1-47)hCT((a)) function.

British journal of pharmacology·2012
Same journal

Relationship Between Long-Term Exposure to Airborne Particulate Matter and the Intrinsic Capacity of Middle-Aged and Older Adults in China: A Retrospective Cohort Study Based on CHARLS.

Clinical and experimental pharmacology & physiology·2026
Same journal

Dapagliflozin Improves Mitochondrial Function to Reduce the Risk of Atrial Fibrillation in a High-Glucose Environment by Activating the AMPK/PGC-1α/SIRT3 Signalling Pathway.

Clinical and experimental pharmacology & physiology·2026
Same journal

Hypertension-Mediated Organ Damage: Pathophysiological Mechanisms, Clinical Consequences, and Implications for Early Risk Stratification.

Clinical and experimental pharmacology & physiology·2026
Same journal

Saikosaponin D Alleviates Atherosclerosis by Regulating Autophagy and Senescence of VSMCs via Inhibiting EPHB2.

Clinical and experimental pharmacology & physiology·2026
Same journal

Noninvasively Evaluating the Cerebral Blood Flow Changes After Surgery in Adult Moyamoya Patients Using 3D Pulsed Arterial Spin Labelling MRI.

Clinical and experimental pharmacology & physiology·2026
Same journal

Targeting S100A8/A9 Ameliorates Heart Failure with Preserved Ejection Fraction by Modulating TLR4/NF-κB-Mediated Inflammation.

Clinical and experimental pharmacology & physiology·2026
See all related articles

Calcitonin gene-related peptide (CGRP) receptor heterogeneity is clarified. What was thought to be a distinct CGRP(2) receptor may be multiple receptors, guiding new drug development for CGRP-related conditions.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Neuropeptide Signaling

Background:

  • Receptor heterogeneity for calcitonin gene-related peptide (CGRP) has been observed for two decades, with distinct CGRP(8-37)-sensitive and -insensitive populations.
  • CGRP(1) receptors are well-defined as CL/RAMP1, sensitive to CGRP(8-37), while CGRP(2) receptor pharmacology remains elusive.
  • The development of CGRP-targeting therapeutics necessitates a clearer understanding of CGRP receptor subtypes.

Purpose of the Study:

  • To investigate the molecular basis of CGRP receptor heterogeneity.
  • To determine if known CGRP-related receptors can explain the pharmacology attributed to the putative CGRP(2) receptor.
  • To aid in the development of selective pharmacological tools for CGRP research and therapeutics.

Main Methods:

Related Experiment Videos

  • Pharmacological characterization of CGRP-activated receptors.
  • Analysis of CGRP and CGRP(8-37) sensitivity across different receptor complexes.
  • Receptor expression studies.

Main Results:

  • The CGRP(1) receptor (CL/RAMP1) is highly sensitive to CGRP(8-37).
  • Receptors such as AMY(1a) (calcitonin receptor/RAMP1) and AM(2) (CL/RAMP3) are activated by CGRP but show reduced sensitivity to CGRP(8-37).
  • These findings suggest that the previously described CGRP(2) receptor pharmacology may arise from a combination of different CGRP-activated receptors.

Conclusions:

  • The 'CGRP(2) receptor' is likely not a single entity but an amalgamation of various CGRP-activated receptors.
  • Specific CGRP-related receptors, like AMY(1a) and AM(2), contribute to the observed CGRP(2) receptor pharmacology.
  • Further studies using selective agonists/antagonists and expression analysis are needed to fully delineate these distinct CGRP receptor populations.